NCT03091426

Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis

A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacodynamics, Safety, Tolerability and Efficacy of Omiganan BID in Patients With Mild to Moderate Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Maruho Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study has a randomized, double-blind, placebo-controlled design to assess the efficacy, pharmacodynamics and safety/tolerability of omiganan in patients with mild to moderate atopic dermatitis when applied BID to all atopic dermatitis lesions.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Omiganan	Omiganan 1%
DRUG	Omiganan	Omiganan 1.75%
DRUG	Omiganan	Omiganan 2.5%
DRUG	Placebo	Vehicle

Timeline

• Start date: 2017-03-08
• Primary completion: 2017-12-20
• Completion: 2017-12-20
• First posted: 2017-03-27
• Last updated: 2017-12-27

Locations

1 site across 1 country: Netherlands